UroGen Pharma Ltd. (URGN)
36.83
-0.15
(-0.41%)
USD |
NASDAQ |
Oct 09, 16:00
36.83
0.00 (0.00%)
After-Hours: 20:00
UroGen Pharma Cash from Operations (Quarterly) : -35.02M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -35.02M |
| March 31, 2026 | -45.32M |
| December 31, 2025 | -42.51M |
| September 30, 2025 | -47.59M |
| June 30, 2025 | -40.17M |
| March 31, 2025 | -42.02M |
| December 31, 2024 | -13.86M |
| September 30, 2024 | -27.85M |
| June 30, 2024 | -23.31M |
| March 31, 2024 | -31.74M |
| December 31, 2023 | -11.98M |
| September 30, 2023 | -16.35M |
| June 30, 2023 | -19.55M |
| March 31, 2023 | -25.81M |
| December 31, 2022 | -20.49M |
| September 30, 2022 | -16.70M |
| June 30, 2022 | -23.11M |
| March 31, 2022 | -24.00M |
| Date | Value |
|---|---|
| December 31, 2021 | -21.69M |
| September 30, 2021 | -18.82M |
| June 30, 2021 | -19.02M |
| March 31, 2021 | -27.40M |
| December 31, 2020 | -23.20M |
| September 30, 2020 | -26.62M |
| June 30, 2020 | -23.82M |
| March 31, 2020 | -35.64M |
| December 31, 2019 | -26.44M |
| September 30, 2019 | -13.29M |
| June 30, 2019 | -14.77M |
| March 31, 2019 | -17.93M |
| December 31, 2018 | -9.781M |
| September 30, 2018 | -8.973M |
| June 30, 2018 | -7.861M |
| March 31, 2018 | -9.624M |
| December 31, 2017 | -6.199M |
| September 30, 2017 | 2.718M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Xencor, Inc. | -55.66M |
| MeiraGTx Holdings Plc | -38.54M |
| Insmed, Inc. | -88.83M |
| Ironwood Pharmaceuticals, Inc. | 58.28M |
| Viking Therapeutics, Inc. | -125.17M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 1.185M |
| Cash from Financing (Quarterly) | 2.186M |
| Free Cash Flow | -170.67M |
| Free Cash Flow Per Share (Quarterly) | -0.6963 |
| Free Cash Flow to Equity (Quarterly) | -34.11M |
| Free Cash Flow to Firm (Quarterly) | -19.56M |
| Free Cash Flow Yield | -9.41% |